Rare Hematology Market Report 2026

Rare Hematology Market Overview

• Rare Hematology market size has reached to $15.47 billion in 2025 • Expected to grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Increasing Prevalence Of Rare Blood Disorders Fueling The Growth Of The Market Due To Genetic Mutations And Inherited Conditions • Market Trend: Advocacy Councils Enhance Care And Awareness For Rare Blood Disorders • North America was the largest region in 2025.

What Is Covered Under Rare Hematology Market?

Rare hematology refers to the study, diagnosis, and treatment of uncommon blood disorders, including rare anemias, clotting disorders, bone marrow failure syndromes, and rare blood cancers. These conditions often have limited treatment options and affect small patient populations. It helps to advance understanding, improve diagnosis, and develop targeted therapies to enhance patient outcomes and quality of life. The main disease types of rare hematology are hemophilia, sickle cell disease, thalassemia, myelodysplastic syndromes, and others. Hemophilia refers to a genetic bleeding disorder in which the blood does not clot properly due to the deficiency or absence of certain clotting factors, leading to excessive bleeding and difficulty in stopping hemorrhages. The various treatment types include gene therapy, stem cell transplantation, blood transfusion, and pharmacotherapy and utilize different diagnostic techniques such as laboratory tests, blood tests, bone marrow biopsies, imaging techniques, magnetic resonance imaging (MRI) scans, ultrasounds, genetic testing, carrier screening, and whole genome sequencing. It finds applications in pediatric and adult, serving end users such as hospitals, specialty clinics, and research institutes.

What Is The Rare Hematology Market Growth Forecast?

The rare hematology market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising investments in gene therapy development, increasing focus on precision medicine for rare diseases, expansion of newborn and carrier screening programs, growing collaboration between research institutes and pharma companies, advances in genomic sequencing technologies. Major trends in the forecast period include increasing adoption of gene and cell therapies, growing use of advanced genetic diagnostics, rising focus on personalized treatment pathways, expansion of specialized rare disease centers, enhanced integration of digital patient monitoring.

What Is The Driver Of The Rare Hematology Market?

The increasing prevalence of rare blood disorders is expected to propel the growth of the rare hematology market going forward. Rare blood disorders refer to uncommon medical conditions that affect the production, function, or lifespan of blood cells or clotting factors, leading to anemia, bleeding disorders, or hemolysis. The prevalence of these disorders is increasing due to genetic mutations and inherited conditions passed from parents to children. The rare hematology market supports this trend by providing specialized diagnostics and targeted therapies that help manage complex and uncommon blood conditions while reducing complications and improving long-term patient outcomes. For instance, in March 2024, according to the National Institute for Health and Care Excellence, a UK-based non-departmental public body, in 2022 and 2023, there were 2,069 individuals in the UK diagnosed with haemophilia B, including 374 with severe disease and 351 with moderate disease. Therefore, the increasing prevalence of rare blood disorders is driving the growth of the rare hematology industry.

Key Players In The Global Rare Hematology Market

Major companies operating in the rare hematology market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., Novartis AG, Astrazeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring LLC, Biogen Inc., Jazz Pharmaceuticals Plc, Octapharma AG, PharmaEssentia Corporation, Disc Medicine Inc., BioInvent International AB, Mustang Bio Inc., BlueSphere Bio Inc., Rallybio LLC

Global Rare Hematology Market Trends and Insights

Major companies operating in the rare hematology market are focusing on developing innovative therapies and strategic initiatives, such as multi-stakeholder advocacy councils, to address unmet medical needs, enhance patient support, and drive cross-indication solutions. Multi-stakeholder advocacy councils are groups of patients, caregivers, and experts collaborating to improve care, awareness, and solutions for a specific health condition. For instance, in February 2023, Agios Pharmaceuticals Inc., a US-based biopharmaceutical company, launched the Red Cell Revolution advocacy advisory council. This initiative brings together patients, caregivers, and healthcare professionals affected by rare hemolytic anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. Its goal is to strengthen community connections, generate published evidence, design practical solutions, and raise awareness of shared challenges. It includes initiatives such as sponsored podcasts, video content, and partnerships with organizations like the National Organization for Rare Disorders to support health equity and education.

What Are Latest Mergers And Acquisitions In The Rare Hematology Market?

In August 2025, Norgine B.V., a Netherlands-based specialty pharmaceutical and consumer healthcare company, acquired Theravia for an undisclosed amount. With this acquisition, Norgine aims to expand and strengthen its portfolio of rare disease medicines and accelerate access to therapies for patients with high unmet medical needs. Theravia Pharmaceuticals is a France-based international pharmaceutical company specializing in providing treatments for rare hematology conditions.

What Defines the Rare Hematology Market?

The rare hematology market includes revenues earned by entities through genetic testing, disease monitoring, blood transfusion support, patient care management, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rare Hematology Market Report 2026?

The rare hematology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rare hematology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.